Altered hepatic blood flow and drug disposition
- PMID: 13954
- DOI: 10.2165/00003088-197601020-00005
Altered hepatic blood flow and drug disposition
Abstract
For some drugs, delivery to the liver by the hepatic circulation is an important determinant of removal by this organ. Classical pharmacokinetic analyses cannot predict the changes produced by altering any of the biological determinants of drug elimination by the liver; hepatic blood flow, metabolic enzyme activity, drug binding and route of administration. However, with the use of a physiological model of hepatic drug elimination, such predictions can be made. This model has been tested experimentally and appears to be valid. Hepatic blood flow can vary over about a 4-fold range from half normal flow to twice logical changes affecting the circulation. For drug clearance to be affected significantly by these changes in flow, the drug must be avidly removed by the liver as reflected in a high hepatic extraction ratio and intrinsic hepatic clearance. This latter term is a useful way to characterise the ability of the liver to irreversibly remove drug from the circulation in the absence of any flow limitation. The clearance of drugs with low intrinsic clearance will not be affected significantly by changes in liver blood flow.
Similar articles
-
Commentary: a physiological approach to hepatic drug clearance.Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377. Clin Pharmacol Ther. 1975. PMID: 1164821
-
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.J Clin Invest. 1974 Apr;53(4):1101-7. doi: 10.1172/JCI107647. J Clin Invest. 1974. PMID: 4205524 Free PMC article.
-
Biological determinants of altered pharmacokinetics in the elderly.Gerontology. 1982;28 Suppl 1:8-17. doi: 10.1159/000212568. Gerontology. 1982. PMID: 7044905 Review.
-
Effects of route of administration and blood flow on hepatic drug elimination.J Pharmacol Exp Ther. 1975 Dec;195(3):424-32. J Pharmacol Exp Ther. 1975. PMID: 1195129
-
A new model-independent physiological approach to study hepatic drug clearance and its applications.Int J Clin Pharmacol Ther Toxicol. 1984 Nov;22(11):577-90. Int J Clin Pharmacol Ther Toxicol. 1984. PMID: 6389376 Review.
Cited by
-
The effect of changes in arterial CO2 tension on plasma lidocaine concentration.Can J Anaesth. 1987 Jul;34(4):343-5. doi: 10.1007/BF03010130. Can J Anaesth. 1987. PMID: 3111736
-
Protein binding of coumarin anticoagulants in disease states.Clin Pharmacokinet. 1977 Mar-Apr;2(2):110-26. doi: 10.2165/00003088-197702020-00003. Clin Pharmacokinet. 1977. PMID: 324687 Review. No abstract available.
-
Lidocaine increases the number of beta-adrenoceptors in neonatal rat cardiocytes in culture.Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):170-4. doi: 10.1007/BF00169833. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 8170500
-
Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.Br J Clin Pharmacol. 1980 Apr;9(4):399-405. doi: 10.1111/j.1365-2125.1980.tb01068.x. Br J Clin Pharmacol. 1980. PMID: 7378257 Free PMC article. Clinical Trial.
-
Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.Eur J Clin Pharmacol. 1986;31(4):397-404. doi: 10.1007/BF00613513. Eur J Clin Pharmacol. 1986. PMID: 3816918
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources